Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event

16 Sept 2020

Abstract excerpt

Hyperdiploidy (HRD) and specific immunoglobulin heavy locus (IGH) translocations are primary chromosomal abnormalities (CA) in multiple myeloma (MM). In this retrospective study of 794 MM patients we aimed to investigate clinical features and common CA including gain(1q) in separate subgroups defined by primary CA. In the entire group, we confirmed that gain(1q) was associated with short time to next treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Glycosylation and Glycoproteins Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32936982
DOI: 10.1002/ajh.25994

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic eventPMID 32936982Read ↗

Chromosome 1q21 abnormalities in multiple myelomaSemantic proximity Read ↗

Gain/Amplification of Chromosome Arm 1q21 in Multiple MyelomaSemantic proximity Read ↗

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cellsSemantic proximity Read ↗

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic TargetsSemantic proximity Read ↗

Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implicationsSemantic proximity Read ↗

Clinical implications of cytogenetic and molecular aberrations in multiple myelomaSemantic proximity Read ↗

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalitiesSemantic proximity Read ↗

Proteasome inhibitors and <scp>IM</scp>iDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21Semantic proximity Read ↗

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesionsSemantic proximity Read ↗

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogeneticsSemantic proximity Read ↗

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic valueSemantic proximity Read ↗

Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.